↓ Skip to main content

RETRACTED ARTICLE: Norcantharidin modulates miR-655-regulated SENP6 protein translation to suppresses invasion of glioblastoma cells

Overview of attention for article published in Tumor Biology, November 2015
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
4 Mendeley
Title
RETRACTED ARTICLE: Norcantharidin modulates miR-655-regulated SENP6 protein translation to suppresses invasion of glioblastoma cells
Published in
Tumor Biology, November 2015
DOI 10.1007/s13277-015-4447-2
Pubmed ID
Authors

Zhenxing Zhang, Xiaofeng Song, Xu Feng, Ye Miao, Honglei Wang, Yang Li, He Tian

Abstract

Norcantharidin (NCTD) is currently used as an anticancer drug for the treatment of some malignant cancers. However, whether it may have therapeutic effects on glioblastoma multiforme (GBM) remains unknown. Moreover, the underlying mechanisms have not been completely elucidated. Recently, SUMO-specific protease 6 (SENP6) has been shown as a tumor suppressor in some cancers. Nevertheless, whether it is involved in the pathogenesis of GBM has not been examined. Here, we studied the effects of NCTD on GBM cells. We found that NCTD dose-dependently increased SENP6 protein, but not messenger RNA (mRNA), in GBM cells, resulting in the suppression of cell invasion. Depletion of SENP6 in GBM cells significantly attenuated the NCTD-induced suppression of GBM cell invasion, while overexpression of SENP6 in GBM cells mimicked the effects of NCTD on cell invasion. Moreover, NCTD dose-dependently decreased the levels of microRNA-655 (miR-655), which bound to 3'-UTR of SENP6 mRNA to inhibit its translation. Overexpression of miR-655 decreased SENP6 in GBM cells, while depletion of miR-655 increased SENP6 protein in GBM cells. Taken together, our data demonstrates a previously unappreciated control of NCTD to suppress GBM cell invasion through modulation of miR-655-regulated SENP6 protein translation.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 4 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 2 50%
Student > Ph. D. Student 1 25%
Other 1 25%
Readers by discipline Count As %
Medicine and Dentistry 1 25%
Engineering 1 25%
Unknown 2 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 November 2015.
All research outputs
#20,297,343
of 22,834,308 outputs
Outputs from Tumor Biology
#1,834
of 2,622 outputs
Outputs of similar age
#324,093
of 386,751 outputs
Outputs of similar age from Tumor Biology
#205
of 319 outputs
Altmetric has tracked 22,834,308 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,622 research outputs from this source. They receive a mean Attention Score of 2.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 386,751 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 319 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.